Uses of dl-THP
- Summary
- dl-THP (dl-tetrahydropalinatine) was only marketed as an herbal supplement or sleeping pill. However, a novel use of dl-THP is available now.
The present invention succeeds in identifying a previously unsuggested binding partner for dl-THP, namely the BDZ (benzodiazepine) binding site of the GABAA receptor. A method of manufacture of a composition (eg. A medicament) for the treatment of CNS (central nervous system) disorders, including the treatment of anxiety and seizures, the composition comprising dl-THP is provided.
Thus, the uses of dl-THP could be expanded and developed into sedative-tranquilizing, anticonvulsant or myorelaxant agents for the treatment of CNS disorders.
- Technology Benefits
- 1. New usage of dl-THP
2. Low toxicity
- Technology Application
- - Potential drugs for the treatment of central nervous system disorders or memory impairment
- Potential anxiolytic, anti-convulsantor sedative-hypustic drugs
- Supplementary Information
- Patent Number: US6521634B2
Application Number: US2001819367A
Inventor: Xue, Hong | Law, Sek Lun
Priority Date: 28 Mar 2001
Priority Number: US6521634B2
Application Date: 28 Mar 2001
Publication Date: 18 Feb 2003
IPC Current: A61K003146 | A61K00314745 | A61P002508 | A61P002522
US Class: 514284
Assignee Applicant: The Hong Kong University of Science & Technology
Title: Uses of dl-THP
Usefulness: Uses of dl-THP
Summary: The method is useful for treating CNS disorders, especially anxiety, seizures, status epilepticus, cerebral palsy and generalized anxiety disorder. It is also useful for achieving an anticonvulsant or anesthetic premedicative effect (claimed).
Novelty: Treatment of central nervous system disorders e.g. anxiety, seizure, status epilepticus, cerebral palsy and generalized anxiety disorder, comprising administration of dl-tetrahydropalmatine
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application Date
- 28 Mar 2001
- Application No.
- US 09/819367
- Patent Information
- US 6521634
- ID No.
- TTC.PA.122
- Country/Region
- Hong Kong
For more information, please click Here
